Clinical trial Recruiting at 1 site Observational

Shanghai clinical cohort for Parkinson's disease and multiple system atrophy (Reserve)

Official title: Shanghai Clinical Cohort - Parkinson's Disease (Reserve)

Run by Ruijin Hospital · NCT07353463 · Data updated 2026-11-12

This project will try to use clinical exams, brain scans, electrical tests, genetic and biosample data from people with Parkinson's disease or multiple system atrophy to find early markers and better subtypes.

More Parkinson's Disease (PD) trials

Quick facts

Study typeObservational
SexAll
Enrollment700 (estimated)
SponsorRuijin Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedApril 1, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMarch 5, 2026
Trial IDNCT07353463 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a clinical diagnosis of Parkinson's disease (per Chinese 2016 criteria) or clinically probable multiple system atrophy (per Chinese 2022 criteria) who are willing to provide informed consent, biospecimens, and undergo neuroimaging and clinical assessments are ideal candidates.

Probably not a fit

People who are unwilling or unable to provide biosamples, undergo imaging or follow-up visits, or who do not meet the clinical diagnostic criteria for PD or MSA are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a longitudinal observational cohort enrolling people with clinical Parkinson's disease and clinically probable multiple system atrophy in Shanghai. Participants will undergo standardized clinical assessments, multimodal imaging (MRI, PET/SPECT), electrophysiology, and biospecimen collection (blood, saliva, optional CSF) with long-term follow-up. Researchers will collect genetic data and compare 600 PD patients to 100 MSA patients to identify biomarkers, define precise subtypes, and model disease progression and treatment response. The assembled dataset is intended as a resource for translational research and development of novel therapies.

Why it matters

Potential benefit: If successful, the cohort could enable earlier diagnosis, more precise subtyping, and better prediction of disease course to guide personalized care.

How similar studies have gone: Multimodal cohort efforts such as PPMI and other longitudinal PD cohorts have found promising biomarker signals and subtype patterns, but translation to routine clinical care remains limited and further validation is needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
* Inclusion Criteria for Clinical PD Group:

  1. Patients with a clinical diagnosis of Parkinson's disease (PD) according to the \_Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)\_.
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent
* Inclusion Criteria for Clinical MSA Group:

  1. Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022).
  2. Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments.
  3. Provision of written informed consent.
* Exclusion Criteria for All Participants:

  1. Patients with an unclear or uncertain diagnosis.
  2. History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery.
  3. Evidence of intracranial organic lesions on CT/MRI.
  4. Severe anxiety, depression, or schizophrenia.
  5. Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system.
  6. Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments.
  7. Anticipated poor compliance.

Where it's running

  • Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.